Granted Patent
B2
US 10,040,769 · App. 15/335,971 · Granted Aug 7, 2018
HDAC inhibitors for the treatment of diabetic peripheral neuropathy
Assignee:
REGENACY PHARMACEUTICALS, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to HDAC inhibitors for use in the treatment of diabetic peripheral neuropathy in a subject in need thereof. Also provided herein are methods for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor.
Claims (3)
1. A method for treating diabetic peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC6-specific inhibitor, wherein the HDAC6-specific inhibitor is:
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the HDAC6-specific inhibitor is administered by oral administration.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 8, 2020
From: GOLONZHKA, OLGA; JARPE, MATTHEW B.
To: ACETYLON PHARMACEUTICALS, INC.
Reel/Frame 051453/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 4, 2018
From: GOLONZHKA, OLGA; JARPE, MATTHEW B.
To: ACETYLON PHARMACEUTICALS, INC.
Reel/Frame 045977/0209 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 4, 2018
From: ACETYLON PHARMACEUTICALS, INC.
To: REGENACY PHARMACEUTICALS, LLC
Reel/Frame 045977/0593 →
Continuity (3)
Provisional Application
62246965
· Oct 27, 2015
Provisional Application
62281990
· Jan 22, 2016
Cited By (2)